Marinus Pharmaceuticals, Inc. [NASDAQ:MRNS]: Analyst Rating and Earnings
Equities traders frequently stay up to date regarding what leading market analysts think about a possible stock buy. As it relates to Marinus Pharmaceuticals, Inc. [MRNS], the latest mean analyst recommendation that’s publicly available is from the fiscal three-month period ending in December. On average, stock market experts give MRNS an Outperform rating. The average 12-month price forecast for this stock is $20.33, with the high estimate being $29.00, the low estimate being $13.00 and the median estimate amounting to $21.50. This is compared to its latest closing price of $3.51.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Marinus Pharmaceuticals, Inc. [MRNS] is sitting at 1.67. This is compared to 1 month ago, when its average rating was 1.67.
Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Tue 5 Mar (In 52 Days).
Fundamental Analysis of Marinus Pharmaceuticals, Inc. [MRNS]
This company’s Return on Total Capital is -44.95. Its Return on Equity is -47.55, and its Return on Assets is -41.03. These metrics suggest that this Marinus Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -6.20. Marinus Pharmaceuticals, Inc. [MRNS] has a Price to Book Ratio of 5.70.
This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 21.37 and its Current Ratio is 21.37. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Marinus Pharmaceuticals, Inc. [MRNS] has 48.98M shares outstanding, amounting to a total market cap of $172.90M. Its stock price has been found in the range of 2.36 to 10.54. At its current price, it has moved by -66.51% from its 52-week high, and it has moved 49.58% from its 52-week low.
This stock’s Beta value is currently 3.32, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 47.51. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Marinus Pharmaceuticals, Inc. [MRNS] a Reliable Buy?
Marinus Pharmaceuticals, Inc. [MRNS] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.